Russia Administers First Personalised Cancer Vaccine to Patient

• Russia has administered its first personalised mRNA cancer vaccine
• The vaccine is tailored to each patient’s tumour, training the immune system to target cancer cells
• The vaccine marks a significant step in the global race for advanced cancer treatments

RUSSIA —Russia has announced a major milestone in cancer treatment, confirming that its first patient has received a personalised mRNA-based cancer vaccine known as Enteromix.

The development signals the country’s entry into a rapidly advancing global race to use cutting-edge technology in the fight against cancer.

Announcement by the Russian Health Ministry

According to News Wire, Russia’s health ministry indicated that the vaccine is designed to offer a highly targeted approach to treatment by tailoring therapy to each patient. Early reports claim promising results, including significant tumour shrinkage in preliminary trials. However, while the breakthrough is generating excitement, experts caution that the vaccine is still in its experimental phase.

Read also

Mzansi researchers prove giant prehistoric insects could survive in our modern atmosphere

Personalised cancer vaccines represent one of the most sophisticated approaches in modern medicine. Unlike traditional treatments, these vaccines are custom-made for each patient.

See post here:

How does this vaccine work?

Scientists begin by sequencing a patient’s tumour to identify specific mutations. From there, they isolate “neoantigens”, unique markers found only in the cancer cells and not in healthy tissue. Using mRNA technology, a vaccine is then developed to train the immune system to recognise and attack these markers.

The vaccine was given to a patient in Russia as part of an early-stage clinical rollout of a domestically developed personalised cancer therapy. The treatment is designed to target specific characteristics of an individual patient’s tumour, rather than using a one-size-fits-all approach.

Officials claim that early trials of Enteromix demonstrated 100% efficacy, with tumour reductions of between 60% and 80% in patients

Russia enters the global race

Russia’s announcement comes amid accelerating global efforts to develop personalised cancer vaccines. International pharmaceutical companies have already made notable progress, with some experimental mRNA vaccines showing encouraging results in reducing cancer recurrence in clinical trials.

Read also

"Reduce your salt": Chicken Licken sparks outrage across Mzansi after scrap rubber band decision

Multiple research programmes are currently underway worldwide, targeting cancers such as melanoma, colorectal cancer and glioblastoma. The science underpinning these vaccines is widely regarded as legitimate and promising, with many experts agreeing that personalised immunotherapy is likely to play a major role in future cancer treatment.

Hope tempered with caution

Despite the optimism, Russia’s announcement has also raised concerns as no peer-reviewed data has yet been released to support these figures.

At this stage, the phrase “administered to a patient” offers limited insight into how far the vaccine has progressed in clinical testing.

If validated through rigorous trials, Enteromix could represent a significant step forward in personalised cancer care.

SA announces HIV vaccine trial

In similar news, South Africa took a historic step in the global fight against HIV, bringing the continent closer to a potential vaccine. Reports indicated that the first-ever human trial of a new HIV vaccine officially began in Cape Town at the Desmond Tutu HIV Foundation, based at Groote Schuur Hospital. This milestone marks a major advancement in Africa’s efforts to tackle the epidemic.

Previously, Briefly News reported that a team of Cape Town doctors successfully used extreme cold temperatures to freeze and destroy recurring thyroid cancer cells for the first time in South Africa. The specialised radiology team achieved this feat on 25 March 2026 by using advanced cryoablation technology to treat a patient suffering from a complex case of thyroid carcinoma.

Source: Briefly News